Germ cell testicular tumors (GCTTs) are the most commonly diagnosed cancer in young men, with cure rates exceeding 95%. Clinical stage 1 (CS1) disease is the most common manifestation, with radical orchiectomy curing the majority of CS1 patients, making active surveillance the treatment of choice, with a cancer specific survival nearing 100% and low relapse rates. However, in metastatic disease, chemotherapy, radiotherapy and surgery are curative options. Chemotherapy remains the mainstay of therapy for advanced disease with surgical management of residual disease. Patients with advanced disease, should be treated in high volume experienced academic centers with multidisciplinary teams. Research exploring refinement of diagnosis and treatment, and lowering treatment burden is underway.
Urology. 2018 Dec 28 [Epub ahead of print]
Hanan Goldberg, Zachary Klaassen, Thenappan Chandrasekar, Neil Fleshner, Robert J Hamilton, Michael A S Jewett
Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Canada. Electronic address: ., Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Canada.